Metastatic Prostate Cancer: Sequential or Combination Therapy?
-
Published:2024-12
Issue:6
Volume:22
Page:102182
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Dottorini Lorenzo,
Petrelli FaustoORCID
Reference14 articles.
1. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017
2. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study;Chi;J Clin Oncol,2021
3. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol;Attard;Lancet Oncol,2023
4. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer;Smith;N Engl J Med,2022
5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015